Stephen F Thung1, William A Grobman. 1. Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Northwestern University Medical School, Chicago, Ill, USA.
Abstract
OBJECTIVE: The purpose of this study was to determine the cost-effectiveness of routine antenatal screening for herpes simplex virus 1 and 2 in women without a known history of genital herpes. STUDY DESIGN: Decision analysis was used to compare 3 treatment strategies to prevent neonatal herpes infection in women without a known history of genital herpes simplex virus: (1) the current standard of care (no herpes simplex virus screening), (2) antepartum herpes simplex virus-1 and -2 antibody screening of the pregnant woman and her male partner with appropriate counseling, and (3) antepartum herpes simplex virus-1 and -2 antibody screening with appropriate counseling and acyclovir prophylaxis at 36 weeks of gestation in seropositive women. RESULTS: Our model predicts that using current guidelines, 1 of 5469 women will have a herpes-infected neonate. Strategy 2 and 3 cost $5,812,819 and $4,130,297, respectively, for every significant neurologic sequela or death prevented. The cost-effectiveness of these strategies, expressed as cost per quality life-year gained, was $219,513 and $155,988 respectively. These results were robust in the sensitivity analysis. CONCLUSION: Routine herpes simplex virus screening in pregnancy is not cost-effective.
OBJECTIVE: The purpose of this study was to determine the cost-effectiveness of routine antenatal screening for herpes simplex virus 1 and 2 in women without a known history of genital herpes. STUDY DESIGN: Decision analysis was used to compare 3 treatment strategies to prevent neonatal herpes infection in women without a known history of genital herpes simplex virus: (1) the current standard of care (no herpes simplex virus screening), (2) antepartum herpes simplex virus-1 and -2 antibody screening of the pregnant woman and her male partner with appropriate counseling, and (3) antepartum herpes simplex virus-1 and -2 antibody screening with appropriate counseling and acyclovir prophylaxis at 36 weeks of gestation in seropositive women. RESULTS: Our model predicts that using current guidelines, 1 of 5469 women will have a herpes-infected neonate. Strategy 2 and 3 cost $5,812,819 and $4,130,297, respectively, for every significant neurologic sequela or death prevented. The cost-effectiveness of these strategies, expressed as cost per quality life-year gained, was $219,513 and $155,988 respectively. These results were robust in the sensitivity analysis. CONCLUSION: Routine herpes simplex virus screening in pregnancy is not cost-effective.
Authors: Carolyn Gardella; Elizabeth Krantz; Constance Daruthayan; Linda Drolette; Lawrence Corey; Anna Wald Journal: Sex Transm Dis Date: 2009-04 Impact factor: 2.830
Authors: Helen C Stankiewicz Karita; Nicholas J Moss; Ellen Laschansky; Linda Drolette; Amalia S Magaret; Stacey Selke; Carolyn Gardella; Anna Wald Journal: Open Forum Infect Dis Date: 2017-11-06 Impact factor: 3.835
Authors: Angela Devine; Xiuqin Xiong; Sami Lynne Gottlieb; Maeve Britto de Mello; Christopher K Fairley; Jason J Ong Journal: Health Qual Life Outcomes Date: 2022-02-16 Impact factor: 3.186